Insider Selling: KalVista Pharmaceuticals (NASDAQ:KALV) Insider Sells 1,489 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) insider Nicole Sweeny sold 1,489 shares of the company’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the insider directly owned 59,291 shares in the company, valued at $1,587,812.98. This trade represents a 2.45% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Nicole Sweeny also recently made the following trade(s):

• On Friday, May 22nd, Nicole Sweeny sold 1,861 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $26.78, for a total transaction of $49,837.58.
• On Friday, April 17th, Nicole Sweeny sold 1,862 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64.

KalVista Pharmaceuticals Stock Down 0.1%

Shares of KALV stock traded down $0.02 on Wednesday, reaching $26.79. 2,466,702 shares of the company were exchanged, compared to its average volume of 2,436,684. The company has a market cap of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12. The company has a 50-day moving average of $21.74 and a 200-day moving average of $17.54. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $26.85.

KalVista Pharmaceuticals (NASDAQ:KALV) last released its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to the consensus estimate of $39.03 million. Analysts anticipate that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current year.

Wall Street Analysts Forecast Growth

KALV has been the topic of a number of research analyst reports. Wall Street Zen cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. JonesTrading cut shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, April 30th. HC Wainwright cut shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price target for the company from $37.00 to $27.00 in a research report on Friday, May 1st. Stifel Nicolaus raised their price target on shares of KalVista Pharmaceuticals from $39.00 to $42.00 and gave the company a “buy” rating in a research report on Thursday, March 26th. Finally, Needham & Company LLC cut shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Hold” and an average target price of $30.60.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Tudor Investment Corp ET AL purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. Jefferies Financial Group Inc. purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $3,494,000. Blue Owl Capital Holdings LP purchased a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $1,522,000. Hennion & Walsh Asset Management Inc. increased its stake in KalVista Pharmaceuticals by 93.6% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock valued at $5,520,000 after buying an additional 165,236 shares during the last quarter. Finally, Skandinaviska Enskilda Banken AB publ increased its stake in KalVista Pharmaceuticals by 391.9% in the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock valued at $2,449,000 after buying an additional 160,128 shares during the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals is a clinical?stage biotechnology company focused on the discovery and development of small?molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.